SEARCH

SEARCH BY CITATION

References

  • 1
    Drossman DD, Corazziari E, Delvaux M, et al. Rome III: The Functional Gastrointestinal Disorders, 3rd edn. McLean, VA: Degnon Associates, Inc., 2006.
  • 2
    Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habits in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005; 128: 5809.
  • 3
    Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 19105.
  • 4
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 5
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 210831.
  • 6
    Lacy BE, Campbell LL. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007; 41: 34551.
  • 7
    Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25: 135161.
  • 8
    Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C117883.
  • 9
    Moeser AJ, Nighot PK, Engelke KJ, Ueno R, Bilkslager AT. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007; 292: 64756.
  • 10
    Amitiza [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc., 2008.
  • 11
    Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 1707.
    Direct Link:
  • 12
    Drossman DD, Corazziari E, Delvaux M, et al. The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, Inc., 2000.
  • 13
    Drossman D, Morris CB, Yuming H, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007; 102: 112.
    Direct Link:
  • 14
    Camilleri M, Mangel AW, Fehnel SE, Drossman DD, Mayer EA, Talley N. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastro Hepatol 2007; 5: 53440.
  • 15
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 210831.
  • 16
    American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S15.
  • 17
    Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S726.
  • 18
    US Food and Drug Administration. Zelnorm (tegaserod maleate) Information. 2008. US FDA Web page: http://www.fda.gov/cder/drug/infopage/zelnorm/default.htm (accessed 30 September 2008).
  • 19
    Patel SM, Stason WB, Legedza A. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 33240.
  • 20
    Mohammad-Panah R, Gyomorey K, Rommens J, et al. ClC-2 contributes to native chloride secretion by a human intestinal cell line, CACO-2. Biol Chem 2001; 276: 830613.
  • 21
    Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C117383.
  • 22
    Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007; 87: 54564.
  • 23
    Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 54552.
  • 24
    Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 128894.
    Direct Link:
  • 25
    Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 131722.
  • 26
    Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42(Suppl. XVII): 417.
  • 27
    Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Ailment Pharmacol Ther 2006; 23: 1916.